initial public offerings (IPOs) trading on American exchanges

Friday, August 15, 2014

Dipexium Pharmaceuticals (DPRX) began trading on the NASDAQ on 13 March 2014

Dipexium Pharmaceuticals, LLC operates as a biopharmaceutical company that develops and commercializes, pexiganan, a small peptide anti-infective agent. It provides Locilex, a small peptide topical antibiotic for the treatment of mild and moderate skin infections in superficial wounds, including infected decubitus ulcers, infected burns, infected surgical wounds, and nasal colonization of methicillin-resistant staphylococcus aureus. The company was founded in 2010 and is based in White Plains, New York.


NEW YORK, NY 10006
United States

Key stats and ratios

Q2 (Jun '14)2013
Net profit margin--
Operating margin--
EBITD margin--
Return on average assets--146.02%
Return on average equity--177.93%

No comments:

Post a Comment